Why You Will Not Get Addicted to CBD

October 28, 2019 08:00:02

Will I get addicted to CBD? That’s the million-dollar question. It is, after all, closely related to the infamous drug marijuana. The cannabis extract is all the rage now, and plenty of people are using it through edibles, CBD pens, medicines, and oils. It is therefore not surprising that many are wondering whether CBD is addictive.

It’s a legitimate question, especially considering the immense demand the products have garnered, coupled with how easily accessible it is. It is only last year that the Farm Bill legalized cultivating industrial hemp, the plant that produces cannabidiol (CBD). Given cannabidiol’s relation to its infamous psychoactive cousin, THC (tetrahydrocannabinol), a cannabinoid wrapped in controversy, it would be natural to pose such a question.

Well, the World Health Organization (WHO) answered this question in a report which examined a ton of things about CBD, including the wonder drug’s potential for abuse. The report said that a “single-dose administration of cannabidiol had been valued healthy in volunteers using a variety of tests of abuse potential as well as physiological effects in a randomized, double-blind placebo-controlled test.”

The report further stated that an orally administered dose of 600mg of CBD did not differ from placebo on the scales of the Addiction Research Inventory, a 16 item Visual Analogue Mood Scale, a subjective level of intoxication, or psychotic symptoms.

A second inspection was conducted, and the report published by WHO says that “the results of this analysis demonstrated that CBD was placebo-like on all measures (including visual analog scales, psychomotor performance such as the digit symbol substitution task, heart rate, and blood pressure).

This is good news for CBD users, especially those that use it to manage medical conditions. Over the years, users have claimed that cannabis products have given them relief from ailments such as chronic pain, insomnia, anxiety, and depression. The FDA even approved a CBD-based drug to treat seizures caused by epilepsy in children. Apart from people with severe issues, there are lots of people using CBD for a variety of other reasons.

The fact that cannabidiol passed abuse potential tests and was found to have no negative attributes is a godsend to such people. They’ll be able to use the CBD products to manage their ailments and get a better quality of life without worrying about getting addicted to their medication.

The debate on the habit-inducing capabilities of cannabis in general still rages on, but CBD uses can rest easy knowing they are safe.

Industry analysts believe that CBD companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and SinglePoint Inc. (OTCQB: SING) have always had a clean conscience due to their belief that CBD isn’t addictive and is safe for all to use.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office